Prime Medicine (PRME) Equity Ratio (2021 - 2026)

Prime Medicine has reported Equity Ratio for 6 years, with the latest figure at 0.26 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio fell 20.13% year-over-year to 0.26; the trailing twelve-month figure through Mar 2026 stood at 0.26 (down 20.13% YoY), and the FY2025 full-year result was 0.35, down 31.49% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.26, down from 0.35 in the prior quarter.
• The five-year high for Equity Ratio was 0.88 in Q1 2023, with the low at 1.04 in Q3 2022.
• Historically, Equity Ratio has averaged 0.48 across 5 years, with a median of 0.57 in 2024.
• Annual changes were most pronounced in 2022 — Equity Ratio soared 269.58% — and 2025, when it plunged 71.18%.
• Prime Medicine's Equity Ratio stood at 0.88 in 2022, then fell by 21.79% to 0.69 in 2023, then dropped by 25.01% to 0.51 in 2024, then plunged by 31.49% to 0.35 in 2025, then slipped by 26.21% to 0.26 in 2026.
• The last three Equity Ratio figures came in at 0.26 (Q1 2026), 0.35 (Q4 2025), and 0.42 (Q3 2025), per Business Quant data.